What is LifeMD, Inc.'s cash and cash equivalents, end of period?

LifeMD, Inc. (LFMD) reported cash and cash equivalents, end of period of $34.48M in Q1 2026.

How has LifeMD, Inc.'s cash and cash equivalents, end of period changed year-over-year?

LifeMD, Inc.'s cash and cash equivalents, end of period increased by 0.2% year-over-year, from $34.39M to $34.48M.

What is the long-term trend for LifeMD, Inc.'s cash and cash equivalents, end of period?

Over 5 years (2020 to 2025), LifeMD, Inc.'s cash and cash equivalents, end of period has grown at a 32.0% compound annual growth rate (CAGR), from $9.18M to $36.79M.

LifeMD, Inc. LFMD Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

PTH

Pelthos Therapeutics Inc.PTHS

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$50.2M-1.4%

Gross profit$44.2M+3.5%

Operating income-$8.9M-656%

Net income-$8.9M-4,728%

EPS (diluted)-$0.20-900%

Balance sheet

See full

Cash & equivalents$34.5M+7.9%

Total debt$6.2M-76.9%

Total equity$15.0M+746%

Total assets$70.1M-4.7%

Cash flow

See full

Operating cash flow$444.6K-85.5%

CapEx$105.2K-10.5%

Free cash flow$339.4K-88.5%

Valuation

See full

Market cap$235.53M-61.7%

Enterprise value$207.22M-66.2%

P/E41.6×—

P/S1.3×-2.3×

Profitability

See full

Gross margin86.1%+0.9pp

Operating margin-9.8%-0.9pp

Net margin3.1%+1.8pp

FCF margin10.4%+1.7pp

Returns & leverage

See full

Return on equity-393.6%—

Debt / equity0.4×—

Current ratio1×+0.2×

Where this comes from

Reported directly by LifeMD, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: LifeMD, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LifeMD, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LifeMD, Inc.'s cash and cash equivalents, end of period?: LifeMD, Inc. (LFMD) reported cash and cash equivalents, end of period of $34.48M in Q1 2026.
How has LifeMD, Inc.'s cash and cash equivalents, end of period changed year-over-year?: LifeMD, Inc.'s cash and cash equivalents, end of period increased by 0.2% year-over-year, from $34.39M to $34.48M.
What is the long-term trend for LifeMD, Inc.'s cash and cash equivalents, end of period?: Over 5 years (2020 to 2025), LifeMD, Inc.'s cash and cash equivalents, end of period has grown at a 32.0% compound annual growth rate (CAGR), from $9.18M to $36.79M.